Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Rhea-AI Summary
Annovis Bio (NYSE:ANVS) completed full enrollment in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer’s disease, enrolling 850 pTau217-positive patients across 83 US sites.
The dual-design study targets 6‑month symptomatic and 18‑month disease‑modifying readouts, with top-line data expected in Q1 2027 and Q1 2028 and planned NDA submissions after each.
Positive
- Pivotal Phase 3 early Alzheimer’s trial fully enrolled with 850 patients
- Enrollment exceeded original patient target, potentially increasing statistical power
- Trial conducted across 83 clinical sites in the United States
- Dual 6‑ and 18‑month readouts designed to support two NDAs
- Top-line symptomatic data expected Q1 2027; disease-modifying data Q1 2028
- Patients selected with pTau217-confirmed Alzheimer’s pathology and MMSE 20–28
Negative
- Efficacy and safety outcomes for buntanetap remain unknown until Phase 3 readouts
- First top-line symptomatic data not expected until Q1 2027
News Market Reaction – ANVS
In the Jul 7 session, ANVS declined 2.54%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.3% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Phase 2/3 results | Positive | -2.1% | Nature NPJ publication of Phase 2/3 buntanetap data showing dose‑dependent benefit. |
| Feb 12 | DSMB safety review | Positive | +2.5% | Independent DSMB cleared pivotal Phase 3 AD trial to continue without changes. |
| Nov 18 | FDA meeting update | Positive | +11.2% | FDA Type C meeting set for PDD and reaffirmed FDA alignment on AD Phase 3 design. |
| Nov 06 | Phase 3 progress | Positive | -2.5% | All AD Phase 3 sites activated with 25% enrollment and first 6‑month completions. |
| Feb 05 | Phase 3 initiation | Positive | +0.0% | First patients entered 18‑month pivotal Phase 3 study for early Alzheimer’s disease. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial headlines have drawn mixed reactions, with several upbeat milestones followed by flat or negative one-day moves.
Key Terms
ptau217 medical
mmse medical
adas-cog13 medical
adcs-iadl medical
new drug application (nda) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections
Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028
Company positions for two NDA submissions following each readout
MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD. The trial enrolled 850 patients with pTau217-confirmed AD pathology across 83 clinical sites in the US.
“Reaching this level of enrollment, well above our original goal, reflects the trust patients and families living with this disease have placed in our work, and that is not something we take for granted,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “This achievement is the product of outstanding trial design, management, and execution led by Cheng Fang, our CSO, and Sarah MacCallum, our VP of Clinical Operations, built from the ground up. I am deeply grateful to them and the entire Annovis team for their professionalism and passion in conducting this study according to the highest standards.”
The pivotal Phase 3 AD study is a randomized, placebo-controlled, double-blind dual clinical trial designed with two pre-specified readouts: a 6-month analysis of symptomatic effects and an 18-month analysis of disease-modifying effects of daily oral buntanetap (30mg). The trial has recruited patients diagnosed with early AD (MMSE 20-28) who are positive for blood biomarker pTau217, which indicates Alzheimer's pathology in the brain. The primary endpoints will assess changes in cognition (ADAS-Cog13) and function (ADCS-iADL). This dual design will produce two distinct data readouts, each intended to support a separate regulatory submission for a New Drug Application (NDA).
Next Milestones
With the last patient expected to complete the 6-month treatment period in January 2027, followed by data cleaning and analysis, Annovis anticipates the following near-term milestones:
- Q1 2027: 6-month symptomatic top-line data readout
- Q1 2028: 18-month disease-modifying top-line data readout
- Regulatory submissions: The Company has already begun preparations for NDA submissions to the U.S. Food and Drug Administration (FDA), building on guidance received during prior FDA interactions, to position Annovis for submission shortly after each respective readout
“That level of enthusiasm from the patient community underscores how urgently a new treatment for Alzheimer's is needed, and how eager people affected by the disease are to help advance it toward the finish line,” said Cheng Fang, Ph.D., CSO at Annovis. “High enrollment also strengthens the statistical power of our dataset. Combined with the FDA-aligned protocol, we are executing this trial according to regulatory requirements as we approach this important moment for our company and the Alzheimer's community.”
“This time last year, our trial had 50 patients enrolled; today, the number stands at 850. We want to thank every patient, caregiver, and investigator who made this progress possible,” said Sarah MacCallum, VP, Clinical Operations at Annovis. “Seamless execution across so many clinical sites and consistent follow-up with every patient throughout this rigorous enrollment process – all required great effort from every party involved, and we are thankful to everyone who helped us reach this milestone.”
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
